Resilient Biotics is a Durham, North Carolina-based biotechnology company pioneering microbiome-based therapeutics for respiratory diseases in both human and animal health.

We are harnessing the power of advanced microbiome genomics and data science to develop innovative preventative and precision treatment strategies. Our proprietary Resilient Analytics platform combines high-resolution genomic analyses, machine learning algorithms, and targeted in vitro assays to identify naturally occurring microbiome-derived strains with immune activation and pathogen inhibition properties.

Resilient Biotics is dedicated to reducing reliance on antibiotics and improving patient outcomes through the targeted modulation of the respiratory microbiome. We are focused on creating a new class of therapeutics that leverages the inherent resilience of the microbiome to combat complex infectious diseases.

Founded in 2017, Resilient Biotics has secured significant venture funding and established strategic partnerships to accelerate the development of its pipeline. Our team, led by Rachelle Galvin and Christopher Belnap, brings together decades of experience in scientific innovation and drug development.

Microbiome Therapeutics | Resilient Biotics

Product description

Resilient Biotics Durham, United States (US)

Price: N/A

Resilient Biotics
Durham, United States (US)